Literature DB >> 18547346

Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.

Daisuke Nonaka1, Luis Chiriboga, Brian P Rubin.   

Abstract

BACKGROUND: Desmoplastic melanoma (DM) may simulate various benign and malignant lesions, including benign peripheral nerve sheath tumors (BPNSTs) and malignant peripheral nerve sheath tumors (MPNSTs). The latter case is diagnostically challenging because DM generally show only S100 protein expression but no reaction to melanocytic markers. S100 family of proteins consists of over 20 members. We report on S100 subtypes in malignant melanomas (MMs), and BPNSTs and MPNSTs to investigate differential expression.
DESIGN: S100A1, S100A2, S100A4, S100A6 and S100B immunostains were performed on 80 MMs including conventional and desmoplastic types, 86 BPNSTs and 77 MPNSTs.
RESULTS: S100A1 expression was seen in > 91% of MMs in a diffuse reaction, whereas BPNSTs showed focal or no reaction. Sixteen percent of MPNSTs focally expressed S100A1 except for one case with diffuse reaction. S100A2 staining was negative or focal in all three groups whereas S100A4 reaction was variable in all three. S100A6 was diffusely expressed in MMs, BPNSTs and MPNSTs. S100B was stained diffusely in MMs and BPNSTs, but its reaction was observed in 30% of MPNSTs in a focal fashion.
CONCLUSION: S100A1 expression was diffuse in most of MMs but absent or focal in BPNSTs and MPNSTs. This may be helpful to distinguish between the two entities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547346     DOI: 10.1111/j.1600-0560.2007.00953.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  32 in total

1.  Spontaneous aortic rupture in a patient with neurofibromatosis type 1.

Authors:  Yang Jin Park; Keun Myoung Park; Jiyoung Oh; Hong Suk Park; Jung-Sun Kim; Young-Wook Kim
Journal:  J Korean Surg Soc       Date:  2012-03-27

2.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

3.  S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.

Authors:  Manal Gabril; Hala Girgis; Andreas Scorilas; Fabio Rotondo; Samantha Wala; Georg A Bjarnason; Qiang Ding; Andrew Evans; Eriny Tawedrous; Maria Pasic; Antonio Finelli; Sahar Al-Haddad; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2016-01       Impact factor: 5.150

4.  Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.

Authors:  Sophie Le Guellec; Nicolas Macagno; Valérie Velasco; Laurence Lamant; Marick Lae; Thomas Filleron; Nausicaa Malissen; Elisabeth Cassagnau; Philippe Terrier; Christine Chevreau; Dominique Ranchere-Vince; Jean-Michel Coindre
Journal:  Mod Pathol       Date:  2017-07-28       Impact factor: 7.842

5.  Desmoplastic melanoma with sarcomatoid dedifferentiation.

Authors:  Maija Kiuru; Gregory McDermott; Michael Berger; Allan C Halpern; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

6.  Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.

Authors:  Ashley Elsensohn; Jessica Shiu; Narina Grove; Anna-Marie Hosking; Ronald Barr; Sébastien de Feraudy
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

7.  S100A1 (S100 calcium binding protein A1).

Authors:  Brian R Cannon; Danna B Zimmer; David J Weber
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2011-10

8.  Thermodynamic and kinetic analysis of peptides derived from CapZ, NDR, p53, HDM2, and HDM4 binding to human S100B.

Authors:  Lucas N Wafer; Werner W Streicher; Scott A McCallum; George I Makhatadze
Journal:  Biochemistry       Date:  2012-08-29       Impact factor: 3.162

9.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

10.  Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2.

Authors:  Joshua P Klopper; Vibha Sharma; Reid Bissonnette; Bryan R Haugen
Journal:  PPAR Res       Date:  2009-10-18       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.